FDA approves single-dose autoinjector for Adbry, an atopic dermatitis treatment by Leo Pharma.
The FDA has approved a new single-dose autoinjector for Adbry (tralokinumab-ldrm), a treatment for atopic dermatitis, made by Leo Pharma. The autoinjector is for use in adults only and will be available in 1- or 2-count pack sizes in the coming months. Adbry, which targets interleukin-13, is intended for patients aged 12 years and older with moderate-to-severe atopic dermatitis whose condition isn't controlled by topical prescription therapies.
June 13, 2024
4 Articles